Issues related to global biopharmaceutical supply chain; Issues related to Section 232 investigations on pharmaceuticals.
2026 · 1st Quarter (Jan 1 - Mar 31)
UCB, INC.
Filed by AKIN GUMP STRAUSS HAUER & FELD.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 20, 2026
- Income
- $80,000.00
- Expenses
- Not reported
- Registrant
- AKIN GUMP STRAUSS HAUER & FELD
- Client
- UCB, INC.
- Filing UUID
- 6df26bbe-7687-476f-b729-8c8a49a161b0
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.